ASCO conference 2018, Press briefing 4 June 2018
- Results of the TAILORx breast cancer trial which correlated Oncotype DX Breast Recurrence Score and impact of chemotherapy on invasive disease–free survival (iDFS) when added to adjuvant ET found that "the vast majority of women who have this test performed on their tumor can be told that they don’t need chemotherapy, and that can be said with tremendous confidence and reassurance”.
- The study results are expected to be immediately practice-changing, Harold Burstein, MD, PhD, FASCO, of Dana-Farber Cancer Institute, commented during the press conference.
Full abstract presented 3 June
TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score.
